Monocrotaline induces interleukin-6 mRNA expression in rat lungs

Area of Science:

• Pulmonary Medicine
• Inflammation Research
• Pharmacology

Background:

• Monocrotaline (MCT) induces pulmonary hypertension (PH) in rats, preceded by lung inflammation and interleukin-6 (IL-6) expression.
• The specific role of IL-6 in the development of MCT-induced PH requires further investigation.

Purpose of the Study:

• To evaluate the role of IL-6 in the pathogenesis of monocrotaline-induced pulmonary hypertension (PH) in a rat model.
• To assess the therapeutic potential of inhibiting IL-6 in MCT-induced PH.

Main Methods:

• Rats were injected with monocrotaline (MCT) or saline. Pulmonary artery pressure (Ppa), right ventricular hypertrophy (RVH), and IL-6 mRNA expression were measured.
• IL-6 bioactivity in lung extracts was assessed. Dexamethasone was used to inhibit IL-6 and evaluate its effects on PH.

Main Results:

• MCT administration led to significant PH and RVH in rats within two weeks.
• IL-6 mRNA expression and IL-6 bioactivity in the lungs progressively increased post-MCT administration.
• Dexamethasone treatment significantly inhibited IL-6 expression and bioactivity, concurrently attenuating PH and RVH.

Conclusions:

• Monocrotaline induces IL-6 expression in rat lungs, contributing to the development of pulmonary hypertension.
• Inhibition of IL-6 signaling can attenuate monocrotaline-induced pulmonary hypertension and right ventricular hypertrophy.
• IL-6 is implicated as a key mediator in the pathogenesis of pulmonary hypertension.